Forschung und Entwicklung

Eine offene, prospektive, multizentrische Phase III-Studie zur Untersuchung der klinischen Wirksamkeit, Sicherheit und pharmakokinetischer Eigenschaften von normalem humanem Immunglobulin zur intravenösen Gabe (BT595) als Ersatztherapie bei Patienten mit einer primären Immundefizienz-Erkrankung (PID)

Eine offene, prospektive, randomisierte, multizentrische Phase III-Studie zur Untersuchung der klinischen Wirksamkeit und Sicherheit von normalem humanem Immunglobulin zur intravenösen Gabe (BT595) bei Patienten mit chronischer primärer Immunthrombozytopenie (ITP)

A randomized, active-controlled, multicenter, phase III study investigating efficacy and safety of intra-operative use of BT524 (human fibrinogen concentrate) in subjects undergoing major spine surgery (AdFIrst).

A prospective, open-label, phase I/III study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenital fibrinogen deficiency.

A randomized, placebo-controlled, double-blind, multi-center, phase II trial investigating the efficacy and safety of trimodulin (BT588) as add-on therapy to standard of care in adult subjects with severe COVID-19.

A prospective, randomized, placebo-controlled, and single-blind Phase I study investigating safety, tolerability, and pharmacokinetic properties of IgM Concentrate BT086 in healthy subjects

A prospective randomized, double-blind, placebo-controlled, multicenter, parallel-group, adaptive group-sequential Phase II Study, to determine the efficacy and safety of BT086 as an adjunctive treatment in severe community acquired pneumonia (sCAP)